Chemlite Innovation Berhad, through its subsidiaries, (0348) Fair Value & Analysis
Industrials · MY · Market cap 132M MYR
Fair value as of: Jun 24, 2026
Analysis
Chemlite Innovation Berhad, through its subsidiaries, (0348) currently trades at 0.2050 MYR, while our model-based Fair Value estimate is 0.1700 MYR — implying the stock looks roughly 17.1% overvalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Chemlite Innovation Berhad, through its subsidiaries, provides surface finishing treatment services in Malaysia, the Philippines, and internationally. The company offers engineering support services, such as metal plating services on intermediate metal products; metal plating services on intermediate metal products, including gold, silver, palladium and/or nickel through electroplating and electroless plating techniques. It also provides non-metal plating services on intermediate metal products comprising anodizing and other non-metal plating services. The company serves semiconductor, telecommunication, medical devices, and automotive sectors. Chemlite Innovation Berhad was founded in 2007 and is headquartered in Simpang Ampat, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Chemlite Innovation Berhad, through its subsidiaries, (0348) undervalued?
What is the fair value of 0348?
What is the quality score of 0348?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.